A Safety, Pharmacokinetic, Pharmacodynamic and Anti-Tumor Study of PF-06873600 as a Single Agent and in Combination With Endocrine Therapy

Condition:   HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer Interventions:   Drug: PF-06873600;   Drug: Endocrine Therapy 1;   Drug: Endocrine Therapy 2 Sponsor:   Pfizer Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials